Aug 2026
Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2−metastatic breast cancer
T. Önder, Öztürk Ateş
· Breast Cancer · 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Aug 2026
Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
Pınar Kubilay Tolunay, Bediz Kurt İnci, B. Karabuğa et al.
· Biomedicines · 0 citations